News

June 20, 2011

Credit

PR – Marketing Dept. 

Customer Conference on 18 June 2011, in Binh Duong

STADA-VN has been acknowledged as one of the most prestigious enterprises on the domestic pharmaceutical market. Recently, STADA-VN has held a “Customer Conference” in Binh Duong province on 18 June 2011 in order to show the deep gratitude to closed partners and customers for their supports during the last time.

image029

Over 200 doctors and pharmacists from hospitals, clinics, pharmacy stores and many agencies in Binh Duong province have attended the conference.

About STELLA

STELLAPHARM is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, anti-viral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.

The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.

Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An Town, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: info@stellapharm.com | W: www.stellapharm.com

You May like

Back
26 Jun 2023

THROUGH THE MPP ORGANIZATION, STELLAPHARM GETS THE 3rd APPROVAL TO PRODUCE SHIONOGI’S COVID-19 ORAL PILL

As one of seven generic drug manufacturers selected by MPP and becoming a sub-licensee of Shionogi – a Japanese pharmaceutical manufacturer to produce of XOCOVA™ drug, generic version. Stellapharm is honored and proud to have contributed to repelling the COVID-19 pandemic with drugs. This is the third oral product in the world to be recognized

01 Oct 2021

Merck says research shows its COVID-19 pill works against variants

Sept 29 (Reuters) – Laboratory studies show that Merck & Co’s (MRK.N) experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta, the company said on Wednesday. Since molnupiravir does not target the spike protein of the virus – the target of